Daniel Tasse
CIK 1502785 · CHIEF EXECUTIVE OFFICER · last filed 2026-06-02
Daniel Tasse is a CHIEF EXECUTIVE OFFICER who has filed 24 SEC Form 4 insider transactions across 3 companies since 2015. The most recent filing, for RGNX, was dated Jun 2, 2026. Across all open-market trades the lifetime net is +$314.2K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $489.9K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$489.9K
3
24
$314.2K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RGNX | Director | 28,861 | $6.66 | $192.2K | $0 | 11 | 2026-06-02 |
| DBVT | CHIEF EXECUTIVE OFFICER | 17,094 | $17.41 | $297.7K | $14.2K | 6 | 2025-11-24 |
| Bellerophon Therapeutics, Inc. (BLPH) Delisted | Director | 182,604 | $0.01 | $2.2K | $300.0K | 7 | 2018-06-25 |
Recent Filings
24 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-02 | RGNX | Grant (A) | +9,807 | $0 | EDGAR |
| 2025-11-24 | DBVT | Grant (A) | — | $0 | EDGAR |
| 2025-06-03 | RGNX | Grant (A) | +7,768 | $0 | EDGAR |
| 2024-12-05 | DBVT | Grant (A) | — | $0 | EDGAR |
| 2024-06-04 | RGNX | Grant (A) | +4,790 | $0 | EDGAR |
| 2024-03-11 | DBVT | Buy (P) | +17,094 | $14.2K | EDGAR |
| 2023-11-22 | DBVT | Grant (A) | — | $0 | EDGAR |
| 2023-08-14 | DBVT | Grant (A) | — | $0 | EDGAR |
| 2023-06-06 | RGNX | Grant (A) | +3,486 | $0 | EDGAR |
| 2022-06-07 | RGNX | Grant (A) | +3,010 | $0 | EDGAR |